Vitamin D expression is decreased in: Breast, CRC, Prostate, Lung, Melanoma, GBM, Pancreatic cancer. (Poor prognosis, with decreased overall survival).
Vitamin D expression is increased in RCC, Thyroid, Ovarian, Endometrial, Cervical cancers (***Better prognosis, with increased overall survival).
See VDR and CYP27B1.
CYP27B1 is the enzyme responsible for converting 25‐hydroxyvitamin D into its active form, 1,25‐dihydroxyvitamin D (calcitriol). As with VDR, CYP27B1 expression in tumors has been investigated for its potential prognostic significance in various cancers.
What Vitamin D Reflects in Cancer
Low 25(OH)D commonly indicates:
-Reduced host resilience (frailty, sarcopenia risk)
-Impaired immune regulation (innate and adaptive)
-Higher inflammatory tone
-Less favorable tumor microenvironment signaling
Vitamin D status therefore integrates nutrition, inflammation, and immune competence.
How Vitamin D Is Used Clinically
A) Prognosis (Primary Use)
-Low vitamin D associates with worse outcomes across several cancers (observational consistency).
-Deficiency correlates with advanced disease and higher mortality.
B) Treatment Tolerance & Supportive Care
-Adequate levels support bone health, muscle function, and may reduce treatment-related complications.
-Correction of deficiency is standard supportive care in many oncology settings.
C) Immune Context (Adjunct)
-VDR signaling modulates cytokine balance, dendritic cell function, and T-cell responses.
-Status helps interpret immune readiness, but is not an immunotherapy selector.
Vitamin D is a meaningful host-state biomarker in oncology. Low levels signal reduced physiological and immune reserve and are associated with poorer outcomes. While it does not guide tumor-specific therapy, maintaining adequate vitamin D is clinically relevant for prognosis, tolerance, and supportive care—making it an important component of the host biomarker layer.
|